CClinicalTrials.gg
CompletedNCT03276325Updated Jan 9, 2018

Epidural Steroids With Intrathecal Nalbuphine for Lower Abdominal Oncologic Surgery

An interventional study of Placebo-nalbuphine and Dexamethasone-nalbuphine in Lower Abdominal Oncologic Surgery, sponsored by Mansoura University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-01-09.

Sponsored by Mansoura University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Intraoperative pain, nausea, vomiting, hypotension, bradycardia are known side effects during lower abdominal surgery under spinal anesthesia, Time to 2 segment regression of sensory block and duration of effective analgesia prolonged with intrathecal (IT) 0.4 mg nalbuphine \& IT 0.8 mg nalbuphine, but the incidence of side-effects was significantly higher with IT 0.8 mg nalbuphine compared with (IT) 0.4 mg nalbuphine.

Read the detailed description

So, the hypothesis of using IT nalbuphine mid away dose 0.6 mg between the best intraoperative analgesic effective dose 0.8 mg and the least side effect producing dose 0.4mg with the addition of epidural dexamethasone could augment the postoperative analgesia and reduce the unwanted side effects. Epidural dexamethasone in a full dose of 8 mg is probably more effective than lower doses to control moderate to severe post-operative pain. Dexamethasone 8mg dose is surgically safe neither produced delayed wound healing nor elevated blood glucose level.

02

Conditions studied

  • Lower Abdominal Oncologic Surgery
03

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • American Society of Anesthesiologists physical class I or II.
  • Undergoing laparotomy
  • Undergoing oophorectomy
  • Undergoing hysterectomy
  • Undergoing rectal mass excision

Exclusion criteria

Exclusion Criteria:

  • Patient refusal.
  • Hypersensitivity to amide local anesthetics.
  • General contraindications to spinal anesthesia.
  • Cardiac diseases.
  • Hepatic failure.
  • Renal failure.
  • Respiratory failure.
  • Communication barriers.
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Placebo comparator
    Placebo-nalbuphine

    Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%

    Drug: Placebo-nalbuphine

  • Active comparator
    Dexamethasone-nalbuphine

    Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%

    Drug: Dexamethasone-nalbuphine

Interventions

  • DrugPlacebo-nalbuphine

    Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%

  • DrugDexamethasone-nalbuphine

    Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%

05

What researchers measure

Primary outcomes

  1. Pain score

    Pain visual analog score (0: no pain, 100: worst imaginable pain)

    Time frame: For 24 hours after surgery

Secondary outcomes

  1. Nausea and vomiting

    (0: no nausea, 1: nausea, 2: mild vomiting, 3: moderate vomiting, 4: severe vomiting)

    Time frame: For 24 hours after surgery

  2. Sensory recovery

    Regression to S1 spinal segment as tested with cold sensation

    Time frame: For 5 hours after induction of anaesthesia

  3. Motor recovery

    The time until decreased a modified Bromage score of 0 (i.e. full leg movement)

    Time frame: For 5 hours after induction of anaesthesia

  4. First analgesic request

    Time to first request of rescue analgesic

    Time frame: For 12 hours after induction of anaesthesia

  5. Intraoperative heart rate changes

    Changes in heart rate during surgery

    Time frame: For 3 hours after induction of anaesthesia

  6. Intraoperative mean arterial blood pressure changes

    Changes in mean arterial blood pressure during surgery

    Time frame: For 3 hours after induction of anaesthesia

  7. Postoperative heart rate changes

    Changes in heart rate after surgery

    Time frame: For 24 hours after surgery

  8. Postoperative mean arterial blood pressure changes

    Changes in mean arterial blood pressure after surgery

    Time frame: For 24 hours after surgery

  9. Cumulative use of antiemetic

    Cumulative use of metoclopramide and ondansetron after surgery

    Time frame: for 24 hrs after surgery

  10. Cumulative use of rescue intravenous ketorolac

    Rescue use of ketorolac in case of severe pain conditions

    Time frame: for 24 hrs after surgery

  11. Cumulative use of rescue intravenous nalbuphine

    Rescue use of nalbuphine in case of severe pain conditions

    Time frame: For 24 hours after surgery

06

Study locations

1 site
  • Mansoura University, Faculty of Medicine
    Mansourah, DK 050, Egypt
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03276325
Lead sponsor
Mansoura University
Responsible party
Sponsor
First posted
Sep 8, 2017
Start date
Sep 15, 2017
Primary completion
Jan 1, 2018
Completion
Jan 7, 2018
Last update
Jan 9, 2018

Study contacts

Mohamed A Ghanem, MD
study chair · Assistant Professor of Anesthesia and Surgical Intensive Care

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion